Bariatric surgery may provide the key to slowing down disease progression in morbidly obese individuals with chronic kidney disease (CKD), according to data presented at ASN Kidney Week 2019, underpinning the role of weight loss in this setting.
A systematic review and meta-analysis evaluating two percutaneous ablation techniques – microwave ablation (MWA) and radiofrequency ablation (RFA) – showed that the former fared better than the latter in reducing local tumour progression (LTP) rates in individuals with hepatocellular carcinoma (HCC) and/or liver metastases.
Any manner of early postoperative diet delivered into the gastrointestinal tract (GIT) following colorectal surgery will help stimulate gut motility, leading to an earlier return of bowel function and a shorter length of hospital stay (LOS), according to a systematic review and meta-analysis.
Among women with severe obesity, undergoing bariatric (Roux-en-Y gastric bypass) surgery prior to conception was associated with a reduced risk of major birth defects in their infants, according to a matched cohort study conducted in Sweden.
Surgery may be a potential treatment for patients who have persistent heartburn due to gastroesophageal reflux disease (GERD) despite treatment with proton-pump inhibitors (PPIs), according to a recent study.
The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.
Treatment with the novel acid secretion inhibitor vonoprazan at 10 mg effectively maintains remission through 52 weeks in patients with proton pump inhibitor (PPI)-resistant reflux oesophagitis, according to the results of a trial from Japan.
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Supplementation with oral nano vitamin D appears to moderate disease activity and severity grade of patients with active ulcerative colitis (UC), suggests a study, adding that this association is more evident in those achieving a target vitamin D level of 40 ng/mL.